The present invention relates to an improved pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55kDa, formulated in a suitable pharmaceutical carrier. The present invention further relates to an improved pharmaceutical, dental and/or cosmetic composition comprising purified Enamel Matrix Derivative (EMD) proteins, which is depleted of proteins which have a molecular weight between 56 and 160kDa and an iso-electric point between 3-10. The improved pharmaceutical, dental and/or cosmetic composition of the present invention comprises purified Enamel Matrix Derivative (EMD) proteins, which are depleted of proteinase inhibitors, such as α1-antichymotrypsin and/or Fetuin A. Said improved composition is herein preferably intended to be used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.Linvention concerne une composition pharmaceutique, dentaire et/ou cosmétique améliorée constituée de protéines de dérivé de matrice de lémail (EMD) à poids moléculaire compris entre 1 et 55KDa, formulée dans un excipient pharmaceutique adapté. Cette invention concerne, en outre, une composition pharmaceutique, dentaire et/ou cosmétique contenant des protéines de dérivé de matrice de lémail (EMD), dépourvue de protéines à poids moléculaire compris entre 56 et 16OkDa et un point iso-électrique compris entre 3-10. La composition pharmaceutique, dentaire et/ou cosmétique améliorée de linvention comprend des protéines de dérivé de matrice de lémail (EMD), qui sont dépourv
